Skip to main content
. 2019 Nov 4;10:1300. doi: 10.3389/fphar.2019.01300

Figure 4.

Figure 4

Incidence of fatal adverse events associated with nivolumab and ipilimumab combination treatment. Abstr, Abstract; CI, Confidence interval.